Alexion Stock Hits New 52-Week High (ALXN)

NEW YORK ( TheStreet) -- Alexion Pharmaceuticals (Nasdaq: ALXN) hit a new 52-week high Tuesday as it is currently trading at $69.39, above its previous 52-week high of $68.50 with 255,841 shares traded as of 10:05 a.m. ET. Average volume has been 1.7 million shares over the past 30 days.

Alexion has a market cap of $12 billion and is part of the health care sector and drugs industry. Shares are up 68.5% year to date as of the close of trading on Monday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company has a P/E ratio of 106.9, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.
  • Practice your ALXN trading strategies and win cash in our stock game.

TheStreet Ratings rates Alexion as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Alexion Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

McDonald's Limited Risk Is Appealing to Conservative Investors

McDonald's Limited Risk Is Appealing to Conservative Investors

Dow Rises as Wall Street Likes Progress in U.S.-China Trade Talks

Dow Rises as Wall Street Likes Progress in U.S.-China Trade Talks

Is McDonald's Stock Worth It?

Is McDonald's Stock Worth It?

Expect Less M&A in 2019 as Big Year Comes to a Close

Expect Less M&A in 2019 as Big Year Comes to a Close

JPMorgan CEO's `Golden Age of Banking' Is Proving Short-Lived

JPMorgan CEO's `Golden Age of Banking' Is Proving Short-Lived